AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Climb Bio to Present at Upcoming Investor Conferences in September 2025.
ByAinvest
Monday, Aug 25, 2025 7:03 am ET1min read
Climb Bio announced its executive team will participate in upcoming investor conferences, including the Cantor Global Healthcare Conference, Baird Global Healthcare Conference, Morgan Stanley Annual Global Healthcare Conference, and Stifel Virtual Immunology and Inflammation Forum. The events will be held in New York and virtually between September 5 and September 10. The live webcasts will be available on Climb Bio's website.
Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company focused on immune-mediated disease therapeutics, has announced its participation in four major investor conferences in September 2025. The company will attend the Cantor Global Healthcare Conference, Baird Global Healthcare Conference, Morgan Stanley Annual Global Healthcare Conference, and Stifel Virtual Immunology and Inflammation Forum [1].The Cantor Global Healthcare Conference will be held in New York on Friday, September 5, 2025, featuring a fireside chat and one-on-one investor meetings. The Baird Global Healthcare Conference will take place on Tuesday, September 9, 2025, also in New York, with a similar format. The Morgan Stanley Annual Global Healthcare Conference, scheduled for Wednesday, September 10, 2025, will consist of one-on-one meetings only. The Stifel Virtual Immunology and Inflammation Forum, also on Wednesday, September 10, 2025, will feature a presentation and one-on-one investor meetings [2].
Climb Bio will provide live webcasts of these events through its investor relations website, with replays available for 30 days after each event. The webcasts can be accessed via the "Investors and News" section of the Climb Bio website [1].
Climb Bio's pipeline includes budoprutug, an anti-CD19 monoclonal antibody with demonstrated B-cell depletion potential, and CLYM116, an anti-APRIL monoclonal antibody currently in IND-enabling studies for IgA nephropathy [1].
References
[1] https://www.stocktitan.net/news/CLYM/climb-bio-to-present-at-upcoming-september-2025-investor-he5rx80touud.html
[2] https://www.globenewswire.com/news-release/2025/08/25/3138331/0/en/Climb-Bio-to-Present-at-Upcoming-September-2025-Investor-Conferences.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet